ISMELIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ismelin, and what generic alternatives are available?
Ismelin is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in ISMELIN is guanethidine monosulfate. There are two drug master file entries for this compound. Additional details are available on the guanethidine monosulfate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ISMELIN?
- What are the global sales for ISMELIN?
- What is Average Wholesale Price for ISMELIN?
Summary for ISMELIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 41 |
| Patent Applications: | 3,488 |
| DailyMed Link: | ISMELIN at DailyMed |
US Patents and Regulatory Information for ISMELIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | ISMELIN | guanethidine monosulfate | TABLET;ORAL | 012329-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | ISMELIN | guanethidine monosulfate | TABLET;ORAL | 012329-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
